Abstract
Background
Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose, which can lead to serious damage of the heart, blood vessels, eyes, kidneys, and nerves. Globally, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014, and the World Health Organization projects that diabetes will be the seventh leading cause of death by 2030. Corresponding author: Sean W. Clark, PharmD West Virginia University School of Pharmacy Waterfront Family Pharmacy, Morgantown, WV Email: swclark@mix.wvu.edu HMG-CoA reductase inhibitors, also known as statins, are proven to reduce the risk of cardiovascular events in patients with diabetes. Because of this proven benefit, the American Diabetes Association and American Heart Association/American College of Cardiology have strong recommendations regarding statin therapy. These organizations recommend that most patients with diabetes, between the age of 40 and 75 and with no contraindications, be started on at least moderate intensity statin therapy. [2] [3] [4] Despite the proven benefit of statin therapy and recommendations by expert panels, its use in patients with diabetes remains low. According to the National Diabetes Statistics Report, 41.8% of adults aged 21 years or older with no self-reported cardiovascular disease, but who were eligible for statin therapy, were not on a lipid-lowering medication. For adults aged 21 years or older with self-reported cardiovascular disease, 33.1% were not on lipid-lowering medication. 5 This gap in care leaves a large proportion of patients with diabetes at risk for the development, or progression, of cardiovascular disease.
The incidence of patients with diabetes not taking statin therapy could be attributed to several factors including therapy intolerance, contraindications, or deficits in knowledge. One study showed that patients have a lack of perceived benefits and underestimate their susceptibility to dyslipidemia-related complications. 6 Based on this information, it appears that rates of statin use in patients with diabetes can be improved through effective patient education programs. [7] [8] Using these tools, pharmacists can work to optimize medication therapy and improve cardiovascular outcomes in patients with diabetes.
Objectives
The objectives of this study were to assess the possible impact of face-to-face patient education on EQuIPP performance scores, determine if face-to-face patient education increased overall knowledge and number of identified patients on statin therapy, and identify barriers to statin therapy in targeted patients with diabetes.
Methods
This prospective targeted intervention study used a patient engagement software program called PrescribeWellness  to identify potential participants at Waterfront Family Pharmacy in Morgantown, WV. This study was approved by the West Virginia University Institutional Review Board. This system identified all eligible participants, regardless of prescription coverage, and included those without Medicare. Participants were approached by investigators at the pharmacy counter when picking up a prescription or contacted via phone to inform them of the project and assess their interest in participation. Investigators also followed up with potential participants via phone if they were unable to be reached during the initial encounter. Data collection started on December 1 st , 2017 and continued until April 30 th , 2018. Participants between the ages of 40 and 75 were included if they received at least two fills of a diabetes medication at the pharmacy in the last year, had not taken a statin within a year prior to being enrolled into the study, and could read and write in English. Participants were excluded if their age was less than 40 or over 75, could not read or write in English, or had any apparent contraindication to statin therapy.
An anonymous written pre-survey (Appendix A) was used to determine demographic data, health history, baseline knowledge about statins, previous statin use, willingness to start a statin, and perceptions about therapy. After completion of the initial survey, participants received education from the project's primary investigator describing the risks and benefits of statin therapy. This education was consistent among participants, and based on a patient education pamphlet (Appendix B) created by investigators. After receiving education, participants were also given a written pamphlet containing the information that was discussed. After the educational intervention, participants received a second anonymous survey (Appendix C) to assess post-education knowledge about statin therapy, willingness to start therapy, and their perceptions about therapy. Following the study period, investigators assessed the number of participants that had received and filled a new prescription for a statin medication. Investigators also calculated the predicted percentage change in the "Statin Use in Diabetes" EQuIPP score and compiled survey responses. The predicted percentage change in EQuIPP scores was calculated instead of the actual change. This method was chosen because EQuIPP data reporting lags approximately 2 months behind data collection and is reported as a 6-month or year-to-date average. It would also be difficult for investigators to account for patients who transferred a prescription into or out of the pharmacy, which could affect the overall score. The score was calculated using the following equation:
Results
Prior to the study period, 56 participants were identified for inclusion. Of these participants, 10 completed the surveys and educational intervention resulting in a 17.8% response rate. The second attempt was completed prior to the end of the study, but was unsuccessful due to lack of interest or inability to make contact. Demographic data collected were as follows; average age of 66 years, 8 identified as male, and 10 identified as Caucasian, having at least a high school education/GED, and having a diagnosis of diabetes.
The "Statin Use in Diabetes" EQuIPP score is reported as a percentage. This score calculates the number of patients with Medicare and diabetes that have filled a prescription for a statin versus the number that have not. A total of 52 participants were included in the "Statin Use in Diabetes" EQuIPP score calculation. This differs from the original 56 identified participants because four were not covered by Medicare. Of the 52 identified participants with Medicare, 13 were not taking a statin which resulted in an overall EQuIPP score of 75% at the beginning of December 2017. The predicted percentage change in this EQuIPP score was calculated based on the number of participants with Medicare taking a statin at the start of the study period, versus the number at the end of the study period. At the conclusion of this study, two participants were started on statin therapy. Of these participants, only one had Medicare and was included in the predicted percentage change in EQuIPP score. The predicted percentage change in the "Statin Use in Diabetes" EQuIPP score was +1.9% (75% to 76.9%).
The overall intervention, including surveys and education, took an average of 18 minutes per participant. Prior to the educational intervention, participant knowledge and background information about statin therapy was assessed. This assessment found that; 70% of participants had heard of a medication called a statin, 30% had spoken to a healthcare provider about statin therapy, 80% preferred to learn about statins from a doctor or pharmacist, and 30% had taken a statin previously and discontinued therapy due to side effects. When participants were asked to identify common indications for statin therapy, a gap in knowledge was observed. This gap in knowledge appeared to improve after the educational intervention. Patient perceptions also changed after the educational intervention and showed a notable shift. These changes in knowledge and perceptions are summarized in Figure 1 .
Discussion
This study showed that, despite the proven benefit of statins reducing the risk of cardiovascular events in patients with diabetes [2] [3] [4] , there was still a need to provide education regarding therapy. The majority of participants had heard of a statin, but did not know it could be used for more than lowering cholesterol levels. This represented a gap in knowledge which may have led to omission of therapy. This gap represents a modifiable factor that could be focused on to reduce the risk of cardiovascular events in patients with diabetes. This study showed that a brief educational intervention may lead to increased patient knowledge, change in perceptions, and an increase in the number of patients with diabetes on statin therapy.
Platforms like EQuIPP can help pharmacists identify patients with opportunities for improved care. This study showed that educating patients about statin therapy could increase quality outcome measures reported by EQuIPP. Even a small increase in the number of patients meeting the outcome measure could have a large impact on the overall score. Improvement of these measures could lead to more comprehensive care and a possible increase in revenue through meeting the quality outcome measures tracked by third party payers.
Limitations to this study included the use of a non-validated survey and small convenience based sample. The results of this study may not be applicable to patients with contraindications or intolerances to statin therapy. A low response rate was an additional study limitation. Of the 56 participants identified, only 10 participated in the study. Of the participants that did not participate, 32 declined to due to time constraints or lack of interest, and 14 could not be reached. New or lost patients were not factored into the predicted EQuIPP score which could influence the actual score. This study used an educational intervention only and did not attempt to contact prescribers regarding statin therapy, which may have resulted in lower rates of newly initiated statins. This study also lacked generalizability to all areas of the United States since it was conducted at a single site, all participants identified as Caucasian, and a majority identified as male.
Future studies should examine the effect of contacting providers as part of the intervention. These studies may also attempt to determine how to increase patient response rates to a face-to-face interaction, or create a more convenient method of contacting patients outside of face-to-face interactions. Lastly, future studies should attempt to identify alternative ways to improve patient education about statin therapy and assess knowledge gained.
Conclusion
In conclusion, this study identified a modifiable factor that may prevent patients from utilizing a therapy proven to reduce or prevent cardiovascular disease associated with diabetes. Pharmacist-provided education is well received by patients and can have a positive influence on knowledge and perceptions, leading to increased rates of statin use in patients with diabetes. Providing education may also have a positive impact on quality outcomes measures tracked by third-party payers through platforms like EQuIPP. Improvement of these scores can help to optimize patient care and potentially increase a pharmacy's revenue by becoming a preferred provider in a third-party payer's network. 
